RxDoctor Payments DataLook up a doctor →

Sibyl Wray, MD

Neurology · Knoxville, TNNPI 1881662591

Payments from drug & device makers

$21,561,966in general payments, 2019–2025

Across 2,108 payments — averaging $10,229 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$15.5M
  • TG Therapeutics, Inc.$1.6M
  • Genentech, Inc.$1.5M
  • Biogen$933K
  • Sanofi$653K
  • F. Hoffmann-la Roche AG$645K
  • plus $694K from 44 others
$2,093,678in research payments, 2019–2025

Across 513 payments — averaging $4081.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$986K
  • Sanofi$941K
  • EMD Serono, Inc.$60K
  • Amgen$42K
  • TG Therapeutics, Inc.$39K
  • Sanofi US Services Inc.$14K
  • plus $11K from 3 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis130$15,504,513
TG Therapeutics, Inc.341$1,631,241
Genentech, Inc.196$1,501,306
Biogen224$932,960
Sanofi223$653,131
F. Hoffmann-la Roche AG413$644,753
Bristol Myers Squibb83$352,401
Roche Products Limited93$67,872
EMD Serono, Inc.70$61,255
Alkermes, Inc.28$52,892
E.r. Squibb & Sons, L.L.C.38$40,675
Jazz Pharmaceuticals Inc.16$29,364
Amgen(2 entities)25$23,219
Eli Lilly2$20,963
Genentech USA, Inc.51$18,904
GW Research Limited3$12,400
Sanofi US Services Inc.2$10,898
Avanir Pharmaceuticals, Inc.28$547
AstraZeneca20$456
Teva Pharmaceuticals USA, Inc.16$289
Supernus Pharmaceuticals, Inc.17$213
Banner Life Sciences, LLC9$210
Johnson & Johnson9$179
Otsuka America Pharmaceutical, Inc.6$135
Lundbeck LLC6$115
AbbVie(2 entities)8$112
Mallinckrodt Hospital Products Inc.5$108
Biohaven Pharmaceuticals, Inc.6$108
Pfizer6$106
Cycle Pharmaceuticals Inc4$67
Takeda Pharmaceuticals U.S.A., Inc.2$59
CSL Behring2$57
Amneal Pharmaceuticals LLC3$53
Acadia Pharmaceuticals Inc3$43
Assertio Therapeutics, Inc.3$41
Sandoz2$37
Tersera Therapeutics LLC1$32
Biohaven Pharmaceutical Holding Company Ltd.2$32
Axsome Therapeutics, Inc.1$27
Argenx US, Inc.1$26
Kedrion Biopharma, Inc.1$24
Grifols USA, LLC1$20
Vanda Pharmaceuticals Inc.1$19
UCB, Inc.1$18
Ironshore Pharmaceuticals Inc.1$16
ANI Pharmaceuticals, Inc.1$16
Zyla Life Sciences, Inc.1$15
Merck1$15
Acorda Therapeutics, Inc1$14
Neurelis, Inc.1$13

How this compares

$21,561,966 in reported general payments places this provider in the 95th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee →

Medicare billing

Part B allowed, 2024
$1,580,556
Medicare patients
218
Services billed
41,431

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Knoxville

See the full list for Tennessee →

Where these figures come from

Is this you, or does something look wrong? →